Lexeo Therapeutics (NASDAQ:LXEO) Receives Buy Rating from Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other brokerages also recently issued reports on LXEO. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Leerink Partners dropped their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Performance

LXEO opened at $3.99 on Tuesday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market cap of $131.93 million, a PE ratio of -1.26 and a beta of 3.85. The business has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $6.65. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, equities analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock valued at $507,000 after acquiring an additional 25,089 shares in the last quarter. Woodline Partners LP raised its holdings in Lexeo Therapeutics by 0.8% during the fourth quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock valued at $5,650,000 after buying an additional 6,730 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after acquiring an additional 350,000 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after acquiring an additional 379,828 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock valued at $934,000 after acquiring an additional 104,837 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.